Cellular Generation and Phenotyping
Our approach is very much to work in partnership with faculty groups for the duration of any project, since due to the evolving nature of cellular biology, protocols often change during the course of a project’s lifespan. Broadly the group’s expertise can be divided into the following key areas:
Currently this is the production of stem cells from skin or blood or the production of organoids from tissue biopsies.
Using techniques such as high content imaging and cell-based bioassays we are able to characterise cells by their surface markers and their responses to stimuli. Such techniques often have application in the validation of gene editing and of therapeutic targets.
The differentiation of precursor cells into a committed linage such as a neuronal cells or macrophages. Ideally differentiation assays are coupled with phenotypic and functional assays to ensure that the resulting cells have the appropriate characteristics.
CRISPR Library Screens
Running whole genome knockout CRISPR libary screens to help idenitfy new drug targets using cancer cell lines, iPSCs and organoid models.
Supplying all cell growth media, differentiation medias, growth factors and coated plates needed by the department and faculty groups with overlapping interests.
Research and Development
Work in the group is underpinned by a research and development function which undertakes continual improvement across the group in order to introduce new techniques and to increase capacity and quality of existing ones.
Cancer Dependency Map
CGaP performs Genome-wide Synthetic-lethal CRISPR-Cas-9 screens in Cancer cell lines and Organoids to identify cancer essential genes.
Deciphering Developmental Disorders (DDD)
DDD-NeuGen is a part of an Open Targets project following on from the Deciphering Developmental Disorders (DDD) study. The aim is ...
EBiSC - European Bank for induced pluripotent Stem Cells
The European Bank for induced pluripotent Stem Cells (EBiSC) is a large European public-private partnership project supported jointly by the ...
Human Cancer Models Initiative (HCMI)
As part of a 2 year pilot phase we have derived over 100 new 3D organoid models from colon, oesophageal and ...
Experimental Cancer Genetics
We are a team of cancer biologists, geneticists and computational biologists interested in understanding how cancers develop and the ways of ...
Genomics of gene regulation
Gene expression involves the transformation of genetic information encoded in DNA sequence into a gene product, such as a protein. Regulation ...
Translational Cancer Genomics
The Translational Cancer Genomics team investigate how genetic alterations in cancer contribute to disease and impact on response to therapy.
In collaboration with our colleagues in Cellular Operations and Stem Cell Informatics, our work focuses on supporting and delivering the gene ...
Genomic mutation and genetic disease
The Hurles group studies the genetic causes and mechanisms of rare genetic disorders and how DNA mutates as it is pass ...
Function of human DNA and its variation
Our goal is to understand how genetic background influences outcome of mutations. To do so, we measure, model, and modulate cell ...
Human-parasite interactions in malaria
Julian Rayner's group investigates the molecular details of human-parasite interactions during the P. falciparum blood stages, with a particular focus ...
Gene expression genomics
We use cutting edge single cell genomics technologies and computational methods to understand genes, proteins and cells in human health and ...
Programmes and Facilities
We work with the following groups
HipSci brings together diverse constituents in genomics, proteomics, cell biology and clinical genetics to create a UK national iPS cell resource and use it to carry out cellular genetic studies. Between 2013 and 2016 we aim to generate iPS cells from over 500 healthy individuals and 500 individuals with genetic disease. We will then use these cells to discover how genomic variation impacts on cellular phenotype and identify new disease mechanisms.
INSIGNIA is a study focused on the investigation of patterns of mutations (signatures) in inherited and other progressive genetic diseases.Cancer is the ultimate genetic disease characterised by many thousands of mutations that accumulate within the genome of a cancer patient. The sets of mutations observed in a cancer genome are the overall outcome of a number of different mutational processes. These are caused by an underlying mechanism of DNA damage, and subsequent attempts by the cell to repair that damage. As a result, each mutational process will leave a distinctive mark or mutational signature on the cancer genome.In the same way that counting tree rings can tell us about the age and growth of that tree, the mutational signatures 'buried in the genome' can provide us with information on the biological changes that have occurred during the course of cancer (or other genetic disease) development.
OpenTargets is a unique public-private initiative to apply cutting edge genetics research to the problem of drug taregt identification and validation. They have generously funded several projects in our lab on the application of CRISPR technology to human IPS-derived model systems